Biofourmis: Predicting Disease, Partnering with Pharma

article image
ARTICLE SUMMARY:

Biofourmis is developing a "predictive care" pipeline of wearable sensors and AI-based digital therapeutics. It operates in a number of clinical areas, and it is also positioning its technology for use in COVID-19 patients. Part four of our series on remote patient monitoring.

Founded in Singapore in 2015 and now based in Boston, start-up Biofourmis Inc. is developing a pipeline of remote monitoring and AI-based digital therapeutics products that co-founder and CEO Kuldeep Singh Rajput says capture and analyze both active and passive data to “predict disease before it happens.” The goal, he says, is to help clinicians intervene early with precise, individualized treatments to improve patient outcomes while minimizing the cost and burden of care—what he refers to as “the right dose to the right patient at the right time.”

×



This article is restricted to subscribers only.

Sign in to continue reading.

Questions?

We're here to help! Please contact us at: